Curcumin and proton pump inhibitors for functional dyspepsia : a randomised, double blind controlled trial
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVE: To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia.
DESIGN: Randomised, double blind controlled trial, with central randomisation.
SETTING: Thai traditional medicine hospital, district hospital, and university hospitals in Thailand.
PARTICIPANTS: Participants with a diagnosis of functional dyspepsia.
INTERVENTIONS: The interventions were curcumin alone (C), omeprazole alone (O), or curcumin plus omeprazole (C+O). Patients in the combination group received two capsules of 250 mg curcumin, four times daily, and one capsule of 20 mg omeprazole once daily for 28 days.
MAIN OUTCOME MEASURES: Functional dyspepsia symptoms on days 28 and 56 were assessed using the Severity of Dyspepsia Assessment (SODA) score. Secondary outcomes were the occurrence of adverse events and serious adverse events.
RESULTS: 206 patients were enrolled in the study and randomly assigned to one of the three groups; 151 patients completed the study. Demographic data (age 49.7±11.9 years; women 73.4%), clinical characteristics and baseline dyspepsia scores were comparable between the three groups. Significant improvements were observed in SODA scores on day 28 in the pain (-4.83, -5.46 and -6.22), non-pain (-2.22, -2.32 and -2.31) and satisfaction (0.39, 0.79 and 0.60) categories for the C+O, C, and O groups, respectively. These improvements were enhanced on day 56 in the pain (-7.19, -8.07 and -8.85), non-pain (-4.09, -4.12 and -3.71) and satisfaction (0.78, 1.07, and 0.81) categories in the C+O, C, and O groups, respectively. No significant differences were observed among the three groups and no serious adverse events occurred.
CONCLUSION: Curcumin and omeprazole had comparable efficacy for functional dyspepsia with no obvious synergistic effect.
TRIAL REGISTRATION NUMBER: TCTR20221208003.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
BMJ evidence-based medicine - 28(2023), 6 vom: 22. Nov., Seite 399-406 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kongkam, Pradermchai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Curcumin |
|---|
| Anmerkungen: |
Date Completed 24.11.2023 Date Revised 24.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjebm-2022-112231 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361940815 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361940815 | ||
| 003 | DE-627 | ||
| 005 | 20231226090214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjebm-2022-112231 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM361940815 | ||
| 035 | |a (NLM)37696679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kongkam, Pradermchai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Curcumin and proton pump inhibitors for functional dyspepsia |b a randomised, double blind controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVE: To compare the efficacy of curcumin versus omeprazole in improving patient reported outcomes in people with dyspepsia | ||
| 520 | |a DESIGN: Randomised, double blind controlled trial, with central randomisation | ||
| 520 | |a SETTING: Thai traditional medicine hospital, district hospital, and university hospitals in Thailand | ||
| 520 | |a PARTICIPANTS: Participants with a diagnosis of functional dyspepsia | ||
| 520 | |a INTERVENTIONS: The interventions were curcumin alone (C), omeprazole alone (O), or curcumin plus omeprazole (C+O). Patients in the combination group received two capsules of 250 mg curcumin, four times daily, and one capsule of 20 mg omeprazole once daily for 28 days | ||
| 520 | |a MAIN OUTCOME MEASURES: Functional dyspepsia symptoms on days 28 and 56 were assessed using the Severity of Dyspepsia Assessment (SODA) score. Secondary outcomes were the occurrence of adverse events and serious adverse events | ||
| 520 | |a RESULTS: 206 patients were enrolled in the study and randomly assigned to one of the three groups; 151 patients completed the study. Demographic data (age 49.7±11.9 years; women 73.4%), clinical characteristics and baseline dyspepsia scores were comparable between the three groups. Significant improvements were observed in SODA scores on day 28 in the pain (-4.83, -5.46 and -6.22), non-pain (-2.22, -2.32 and -2.31) and satisfaction (0.39, 0.79 and 0.60) categories for the C+O, C, and O groups, respectively. These improvements were enhanced on day 56 in the pain (-7.19, -8.07 and -8.85), non-pain (-4.09, -4.12 and -3.71) and satisfaction (0.78, 1.07, and 0.81) categories in the C+O, C, and O groups, respectively. No significant differences were observed among the three groups and no serious adverse events occurred | ||
| 520 | |a CONCLUSION: Curcumin and omeprazole had comparable efficacy for functional dyspepsia with no obvious synergistic effect | ||
| 520 | |a TRIAL REGISTRATION NUMBER: TCTR20221208003 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a digestive system disease | |
| 650 | 4 | |a general practice | |
| 650 | 4 | |a integrative medicine | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 650 | 7 | |a Omeprazole |2 NLM | |
| 650 | 7 | |a KG60484QX9 |2 NLM | |
| 700 | 1 | |a Khongkha, Wichittra |e verfasserin |4 aut | |
| 700 | 1 | |a Lopimpisuth, Chawin |e verfasserin |4 aut | |
| 700 | 1 | |a Chumsri, Chitsanucha |e verfasserin |4 aut | |
| 700 | 1 | |a Kosarussawadee, Prach |e verfasserin |4 aut | |
| 700 | 1 | |a Phutrakool, Phanupong |e verfasserin |4 aut | |
| 700 | 1 | |a Khamsai, Sittichai |e verfasserin |4 aut | |
| 700 | 1 | |a Sawanyawisuth, Kittisak |e verfasserin |4 aut | |
| 700 | 1 | |a Sura, Thanyachai |e verfasserin |4 aut | |
| 700 | 1 | |a Phisalprapa, Pochamana |e verfasserin |4 aut | |
| 700 | 1 | |a Buamahakul, Thanwa |e verfasserin |4 aut | |
| 700 | 1 | |a Siwamogsatham, Sarawut |e verfasserin |4 aut | |
| 700 | 1 | |a Angsusing, Jaenjira |e verfasserin |4 aut | |
| 700 | 1 | |a Poonniam, Pratchayanan |e verfasserin |4 aut | |
| 700 | 1 | |a Wanaratna, Kulthanit |e verfasserin |4 aut | |
| 700 | 1 | |a Teerachaisakul, Monthaka |e verfasserin |4 aut | |
| 700 | 1 | |a Pongpirul, Krit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ evidence-based medicine |d 2018 |g 28(2023), 6 vom: 22. Nov., Seite 399-406 |w (DE-627)NLM279942753 |x 2515-4478 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:6 |g day:22 |g month:11 |g pages:399-406 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjebm-2022-112231 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 6 |b 22 |c 11 |h 399-406 | ||